Blueprint Medicines Corp (BPMC) Shares Bought by State of Wisconsin Investment Board
State of Wisconsin Investment Board raised its position in shares of Blueprint Medicines Corp (NASDAQ:BPMC) by 42.2% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 38,400 shares of the biotechnology company’s stock after purchasing an additional 11,400 shares during the period. State of Wisconsin Investment Board’s holdings in Blueprint Medicines were worth $2,896,000 as of its most recent filing with the Securities & Exchange Commission.
A number of other hedge funds and other institutional investors have also recently modified their holdings of BPMC. Zurcher Kantonalbank Zurich Cantonalbank raised its position in Blueprint Medicines by 57.3% during the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 1,866 shares of the biotechnology company’s stock valued at $141,000 after purchasing an additional 680 shares in the last quarter. Ameritas Investment Partners Inc. raised its position in Blueprint Medicines by 68.9% during the 2nd quarter. Ameritas Investment Partners Inc. now owns 3,410 shares of the biotechnology company’s stock valued at $173,000 after purchasing an additional 1,391 shares in the last quarter. First Mercantile Trust Co. bought a new stake in Blueprint Medicines during the 4th quarter valued at $183,000. Turner Investments LLC bought a new stake in Blueprint Medicines during the 3rd quarter valued at $209,000. Finally, Public Employees Retirement Association of Colorado bought a new stake in Blueprint Medicines during the 4th quarter valued at $227,000. 89.28% of the stock is owned by institutional investors and hedge funds.
In related news, Director Nicholas Lydon sold 25,000 shares of the business’s stock in a transaction on Wednesday, February 28th. The stock was sold at an average price of $87.89, for a total transaction of $2,197,250.00. Following the transaction, the director now directly owns 193,131 shares in the company, valued at approximately $16,974,283.59. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. Also, Director Daniel Lynch sold 17,500 shares of the business’s stock in a transaction on Monday, February 12th. The stock was sold at an average price of $74.84, for a total value of $1,309,700.00. Following the transaction, the director now owns 202,812 shares in the company, valued at $15,178,450.08. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 61,775 shares of company stock worth $5,019,851. 3.40% of the stock is owned by company insiders.
Blueprint Medicines (NASDAQ:BPMC) last announced its earnings results on Wednesday, February 21st. The biotechnology company reported ($1.23) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.07) by ($0.16). Blueprint Medicines had a negative return on equity of 38.79% and a negative net margin of 691.30%. The business had revenue of $1.63 million for the quarter, compared to analysts’ expectations of $5.28 million. During the same quarter last year, the firm earned ($0.75) earnings per share. The firm’s quarterly revenue was down 78.8% compared to the same quarter last year. sell-side analysts anticipate that Blueprint Medicines Corp will post -4.85 earnings per share for the current fiscal year.
BPMC has been the topic of a number of analyst reports. Wedbush reiterated an “outperform” rating and issued a $82.00 price target (up from $70.00) on shares of Blueprint Medicines in a report on Monday, November 6th. Cowen reiterated a “buy” rating on shares of Blueprint Medicines in a report on Friday, November 10th. ValuEngine downgraded Blueprint Medicines from a “hold” rating to a “sell” rating in a report on Friday, December 1st. BidaskClub downgraded Blueprint Medicines from a “buy” rating to a “hold” rating in a report on Wednesday, December 6th. Finally, JMP Securities lifted their price target on Blueprint Medicines from $88.00 to $97.00 and gave the company an “outperform” rating in a report on Monday, December 11th. Two analysts have rated the stock with a sell rating and eleven have assigned a buy rating to the company’s stock. The company has a consensus rating of “Buy” and a consensus target price of $84.20.
TRADEMARK VIOLATION NOTICE: This story was first reported by Daily Political and is the property of of Daily Political. If you are viewing this story on another domain, it was illegally copied and reposted in violation of US and international trademark and copyright legislation. The correct version of this story can be accessed at https://www.dailypolitical.com/2018/03/03/blueprint-medicines-corp-bpmc-shares-bought-by-state-of-wisconsin-investment-board.html.
About Blueprint Medicines
Blueprint Medicines Corporation is a biopharmaceutical company. The Company focuses on patients with genomically defined diseases driven by abnormal kinase activation. It focuses on crafting drug candidates that provide clinical responses to patients without adequate treatment options. It has developed a small molecule drug pipeline in cancer and a genetic disease.
Want to see what other hedge funds are holding BPMC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Blueprint Medicines Corp (NASDAQ:BPMC).
Receive News & Ratings for Blueprint Medicines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Blueprint Medicines and related companies with MarketBeat.com's FREE daily email newsletter.